Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 s...
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design
About this item
Full title
Author / Creator
Publisher
Germany: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
Germany: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Cancer cachexia is a multifactorial metabolic wasting syndrome characterized by anorexia, unintentional loss of weight involving both skeletal muscle and adipose tissues, progressive functional impairment and reduced survival. Therapeutic strategies for this serious condition are very limited. Growth differentiation factor 15 (GDF‐15)...
Alternative Titles
Full title
Phase 2 study of the efficacy and safety of ponsegromab in patients with cancer cachexia: PROACC‐1 study design
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_43771e5cd792467db7f7100408a7e000
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_43771e5cd792467db7f7100408a7e000
Other Identifiers
ISSN
2190-5991,2190-6009
E-ISSN
2190-6009
DOI
10.1002/jcsm.13435
